CancerVax
Rockville
About CancerVax
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 10,001+
- Total funding: $146.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Oct 2008)
- Ticker: nasdaq:MITI
- Website: cancervax.com
- Phone: +490898952770
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cancervax-2903203 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.